专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005056550A3 HETEROCYCLIC ANTI-MIGRAINE AGENTS 审中-公开
标题翻译：杂环抗偏移剂
公开(公告)号：WO2005056550A3
公开(公告)日：2005-07-14
申请号：PCT/US2004040721
申请日：2004-12-06
申请人： SQUIBB BRISTOL MYERS CO , LUO GUANGLIN , CHEN LING , DEGNAN ANDREW P , DUBOWCHIK GENE M , MACOR JOHN E , TORA GEORGE O , CHATURVEDULA PRASAD V
发明人： LUO GUANGLIN , CHEN LING , DEGNAN ANDREW P , DUBOWCHIK GENE M , MACOR JOHN E , TORA GEORGE O , CHATURVEDULA PRASAD V
IPC分类号： C07D401/14 , C07D413/14 , C07D471/10 , C07D401/10 , A61K31/404 , A61K31/41 , A61K31/517 , A61P29/00
CPC分类号： C07D471/10 , C07D401/14 , C07D413/14
摘要： The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
摘要翻译：本发明涉及作为降钙素基因相关肽受体拮抗剂的式（I）化合物（“CGRP-受体”），包含它们的药物组合物，鉴定它们的方法，使用它们的治疗方法以及它们在治疗疗法中的用途神经源性血管舒张，神经源性炎症，偏头痛和其他头痛，热损伤，循环休克，与绝经相关的潮红，气道炎性疾病如哮喘和慢性阻塞性肺病（COPD），以及其它可以通过治疗 CGRP受体的拮抗作用。

2. 发明申请

WO2007121389A2 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS 审中-公开
标题翻译： NK-1和SEROTONIN运输机抑制剂
公开(公告)号：WO2007121389A2
公开(公告)日：2007-10-25
申请号：PCT/US2007066682
申请日：2007-04-16
申请人： SQUIBB BRISTOL MYERS CO , DENHART DEREK J , DEGNAN ANDREW P , TORA GEORGE O , HAN YING , RAMKUMAR RAJAMANI , DITTA JONATHAN L , GILLMAN KEVIN W
发明人： DENHART DEREK J , DEGNAN ANDREW P , TORA GEORGE O , HAN YING , RAMKUMAR RAJAMANI , DITTA JONATHAN L , GILLMAN KEVIN W
IPC分类号： C07D211/22 , A61K31/4465 , A61K31/4525 , A61K31/4535 , C07D401/12 , C07D407/12 , C07D409/12
CPC分类号： C07D401/12 , C07D211/22 , C07D405/12 , C07D409/12 , C07D417/12
摘要： The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both. [ I ]
摘要翻译：本发明包括式I化合物，包括其药学上可接受的盐，其药物组合物及其在治疗与速激肽或5-羟色胺或两者的过量或不平衡相关的疾病中的用途。 [ 一世 ]

3. 发明专利

IL293027A Compounds useful as inhibitors of helios protein 未知
公开(公告)号：IL293027A
公开(公告)日：2022-07-01
申请号：IL29302722
申请日：2022-05-16
申请人： SQUIBB BRISTOL MYERS CO , DEGNAN ANDREW P , KUMI GODWIN KWAME , HUANG AUDRIS , BALOG JAMES AARON , PURANDARE ASHOK VINAYAK , SHAN WEIFANG , GUO LI
发明人： DEGNAN ANDREW P , KUMI GODWIN KWAME , HUANG AUDRIS , BALOG JAMES AARON , PURANDARE ASHOK VINAYAK , SHAN WEIFANG , GUO LI
IPC分类号： A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P35/00
摘要： and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

4. 发明公开

EP1539766A4 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 有权
标题翻译：降钙素相关肽受体拮抗剂
公开(公告)号：EP1539766A4
公开(公告)日：2007-08-08
申请号：EP03736721
申请日：2003-05-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： CHATURVEDULA PRASAD V , CHEN LING , CIVIELLO RITA , CONWAY CHARLES MARK , DEGNAN ANDREW P , DUBOWCHIK GENE M , HAN XIAOJUN , KARAGEORGE GEORGE N , LUO GUANGLIN , MACOR JOHN E , POINDEXTER GRAHAM , VIG SHIKHA
IPC分类号： C07D487/04 , A01K67/027 , A61K31/438 , A61K31/4427 , A61K31/4545 , A61K31/496 , A61K31/517 , A61K31/519 , A61K31/527 , A61K31/537 , A61K31/5377 , A61K49/00 , A61P9/00 , A61P11/00 , A61P11/06 , A61P15/12 , A61P17/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P29/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10 , C07D487/14 , C07D487/22 , C07D491/10 , C07D491/113 , C07D498/10 , C07D519/00 , C12N15/85 , G01N33/566
CPC分类号： A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2227/106 , A01K2267/0306 , A61K49/0008 , C07D401/14 , C07D405/14 , C07D409/14 , C07D471/10 , C07D487/04 , C07D487/14 , C07D491/10 , C12N15/8509 , G01N33/566 , G01N2500/10 , G01N2800/2807
摘要： The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

5. 发明公开

EP1689493A4 CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS 审中-公开
标题翻译： ANTAGONISTEN DES CALCITONIN基因相关肽
公开(公告)号：EP1689493A4
公开(公告)日：2008-04-23
申请号：EP03819270
申请日：2003-12-05
申请人： SQUIBB BRISTOL MYERS CO
发明人： DEGNAN ANDREW P , CHEN LING , CIVIELLO RITA , DUBOWCHIK GENE M , HAN XIAOJUN , JIANG XIANG JUN J , MACOR JOHN E , TORA GEORGE , LUO GUANGLIN
IPC分类号： C07D401/14 , A61K31/495 , A61K31/50 , A61K31/517 , A61K31/52 , A61K31/535 , A61K31/54 , A61K31/55 , A61P25/06 , C07D209/08 , C07D213/64 , C07D221/00 , C07D231/56 , C07D239/00 , C07D239/80 , C07D243/10 , C07D249/18 , C07D263/58 , C07D265/00 , C07D285/00 , C07D317/00 , C07D401/06 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/12 , C07D417/14 , C07D471/04 , C07D471/10 , C07D491/10 , C07D498/10
CPC分类号： C07D471/04 , C07D209/08 , C07D231/56 , C07D249/18 , C07D401/06 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/10 , C07D491/10
摘要： The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors ('CGRP-receptor'), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

6. 发明专利

IL296676A Substituted oxoisoindoline compounds for the treatment of cancer 未知
公开(公告)号：IL296676A
公开(公告)日：2022-11-01
申请号：IL29667622
申请日：2022-09-20
申请人： BRISTOL MYERS SQUIBB CO , DEGNAN ANDREW P , KUMI GODWIN KWAME , TEBBEN ANDREW J , HUANG AUDRIS , PARK PETER KINAM , BILDER DONNA M , CHERNEY EMILY , PURANDARE ASHOK V
发明人： DEGNAN ANDREW P , KUMI GODWIN KWAME , TEBBEN ANDREW J , HUANG AUDRIS , PARK PETER KINAM , BILDER DONNA M , CHERNEY EMILY , PURANDARE ASHOK V
IPC分类号： A61P35/00
摘要： Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

7. 发明公开

EP3294739A1 TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS 有权
公开(公告)号：EP3294739A1
公开(公告)日：2018-03-21
申请号：EP16728765
申请日：2016-05-11
申请人： SQUIBB BRISTOL MYERS CO
发明人： NORRIS DEREK J , VACCARO WAYNE , DEBENEDETTO MIKKEL V , DEGNAN ANDREW P , DELUCCA GEORGE V , DESKUS JEFFREY A , HAN WEN CHING , KUMI GODWIN KWAME , SCHMITZ WILLIAM D , STARRETT JOHN E JR , HILL MATTHEW D , HUANG HONG
IPC分类号： C07D471/14 , A61K31/437 , A61P35/02
CPC分类号： C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , C07D519/00 , C07F9/6561
摘要： wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

8. 发明专利

ES2746131T3 Compuestos tricíclicos como agentes antineoplásicos 未知
公开(公告)号：ES2746131T3
公开(公告)日：2020-03-04
申请号：ES16728765
申请日：2016-05-11
申请人： SQUIBB BRISTOL MYERS CO
发明人： NORRIS DEREK J , VACCARO WAYNE , DEBENEDETTO MIKKEL V , DEGNAN ANDREW P , DE LUCCA GEORGE V , DESKUS JEFFREY A , HAN WEN-CHING , KUMI GODWIN KWAME , SCHMITZ WILLIAM D , STARRETT JOHN E , HILL MATTHEW D , HUANG HONG
IPC分类号： C07D471/14 , A61K31/4375 , A61K31/439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/554 , A61K31/675 , A61K31/683 , A61P35/00 , C07D519/00
摘要： Un compuesto de la fórmula**Fórmula** en donde: U1, U2, U3 y U4 son independientemente -N- o -CH-, con la condición de que uno de ellos sea -N-;**Fórmula** A es R es independientemente uno o más de hidrógeno, CD3, halógeno, haloalquilo, hidroxialquilo, CN, CF3, CH2F, CHF2, alquilo (C1-C6) opcionalmente sustituido, alcoxi (C1-C6) opcionalmente sustituido, cicloalquilo (C3-C6) opcionalmente sustituido, heterociclo opcionalmente sustituido, -OR4, -CONR3R4, -NR3R4, NR3R4alquil (C1-C6)-, - NR6OCOR3, -NR6COR3, NR6COR3alquil (C1-C6)-, -NR6CO2R3, NR6CO2R3alquil (C1-C6)-, -NR6CONR3R4, - SO2NR3R4, SO2alquil (C1-C6)-, -NR6SO2NR3R4, -NR6SO2R4 o NR6SO2R4alquil (C1-C6)-; X e Y se seleccionan independientemente entre hidrógeno, alquilo (C1-C6) opcionalmente sustituido, cicloalquilo (C3-C8) opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heterociclo opcionalmente sustituido; Z es hidrógeno, halógeno, -OH, alquilo (C1-C6) o alcoxi (C1-C6); R1 es, independientemente en cada caso, uno o más de hidrógeno, halógeno, -CN, -OR4, -NR3R4, -CONR3R4, - COOH, -OCONR3R4, -NR6OCOR3, -NR6CONR3R4, -NR6SO2NR3R4, -NR6SO2R4, alquilo (C1-C6) opcionalmente sustituido, alquenilo (C2-C6) opcionalmente sustituido, alquinilo (C2-C6) opcionalmente sustituido, alcoxi (C1-C6) opcionalmente sustituido, cicloalquilo (C3-C8) opcionalmente sustituido, cicloalquil (C3-C8)alquilo (C1-C6) opcionalmente sustituido, cicloalquil (C3-C8)-CO- opcionalmente sustituido, cicloalquil (C3-C8)-SO2- opcionalmente sustituido, arilalcoxi (C1-C6) opcionalmente sustituido, cicloalquil (C3-C8)alcoxi (C1-C6) opcionalmente sustituido, heterociclil-CO- opcionalmente sustituido, heterociclilo opcionalmente sustituido, alquil (C1-C6)-SO2- opcionalmente sustituido, -NR6SO2-alquilo (C1-C6) opcionalmente sustituido, -NR6SO2-heterociclo opcionalmente sustituido, alquil (C1-C6) opcionalmente sustituido-NR6SO2- o heterociclo opcionalmente sustituido-NR6SO2-; R2 es hidrógeno, halógeno, -CN, OH, -CONR3R4, -NR6COOR4, -NR6CONR3R4, -NR6COR4, -NR6SO2R5, - SO2NR3R4, -NR6SO2NR3R4, alquilo (C1-C6) opcionalmente sustituido, cicloalquilo (C3-C8) opcionalmente sustituido, alcoxi (C1-C6) opcionalmente sustituido, arilo opcionalmente sustituido, alquil (C1-C6)-SO2- opcionalmente sustituido, aril-SO2 opcionalmente sustituido, heteroarilo opcionalmente sustituido o heterociclo opcionalmente sustituido; R3 es hidrógeno, alquilo (C1-C6) opcionalmente sustituido, cicloalquilo (C3-C8) opcionalmente sustituido, alquenilo (C2-C6) opcionalmente sustituido, alquinilo (C2-C6) opcionalmente sustituido, cianoalquilo (C1-C6), hidroxialquilo (C1-C6), arilo opcionalmente sustituido, arilalquilo (C1-C6) opcionalmente sustituido, ariloxialquilo (C1-C6) opcionalmente sustituido, alquil (C1-C6)-SO2- opcionalmente sustituido, heterociclilo opcionalmente sustituido, heterociclilalquilo (C1-C6) opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo (C1-C6) opcionalmente sustituido, R4 es hidrógeno, alquilo (C1-C6) opcionalmente sustituido o cicloalquilo (C3-C8) opcionalmente sustituido; R5 es hidrógeno, alquilo (C1-C6) opcionalmente sustituido, cicloalquilo (C3-C8) opcionalmente sustituido, alquenilo (C2-C6) opcionalmente sustituido, alquinilo (C2-C6) opcionalmente sustituido, cianoalquilo (C1-C6), hidroxialquilo (C1-C6), arilo opcionalmente sustituido, arilalquilo (C1-C6) opcionalmente sustituido, ariloxialquilo (C1-C6) 15 opcionalmente sustituido, alquil (C1-C6)-SO2- opcionalmente sustituido, heterociclilo opcionalmente sustituido, heterociclilalquilo (C1-C6) opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroarilalquilo (C1-C6) opcionalmente sustituido; R6 es hidrógeno o alquilo (C1-C6) opcionalmente sustituido; o una sal, un tautómero o un estereoisómero farmacéuticamente aceptables del mismo.

9. 发明专利

MA39211B1 Composés tricycliques comme agents anti-cancers 未知
公开(公告)号：MA39211B1
公开(公告)日：2019-01-31
申请号：MA39211
申请日：2014-12-23
申请人： SQUIBB BRISTOL MYERS CO
发明人： GAVAI ASHVINIKUMAR V , DELUCCA GEORGE V , O'MALLEY DANIEL , GILL PATRICE , QUESNELLE CLAUDE A , LEE FRANCIS Y , TOKARSKI JOHN S , NORRIS DEREK J , VACCARO WAYNE , DEBENEDETTO MIKKEL V , DEGNAN ANDREW P , FANG HAIQUAN , HILL MATTHEW D , HUANG HONG , SCHMITZ WILLIAM D , STARRETT JOHN E , HAN WEN-CHING , MANDAL SUNIL KUMAR
IPC分类号： A61K31/437 , A61P35/00 , C07D471/04
摘要： La présente invention concerne des composés tricycliques (i), des compositions pharmaceutiquement acceptables contenant des composés de l'invention et des procédés d'utilisation desdites compositions dans le traitement de divers troubles.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式